TY - JOUR
T1 - Seminal Papers in Urology
T2 - Darolutamide and survival in metastatic, hormone-sensitive prostate cancer
AU - Oh, Claris
AU - O’Callaghan, Michael
PY - 2024/7/1
Y1 - 2024/7/1
N2 - The ARASENS trial recruited 1306 men with metastatic hormone sensitive prostate cancer. It investigated the effect of androgen deprivation therapy (ADT) and systemic therapy docetaxel in combination with a third novel drug – daralutamide, compared with placebo on overall survival. Triple therapy with ADT, docetaxel and darolutamide resulted in improved overall survival rates as compared with ADT, docetaxel and placebo (HR 0.68; 95% CI, 0.57–0.80; p < 0.001). The side effect profile for both treatments was similar. This randomised, double blinded, placebo controlled study, was assessed to have a low risk of bias using the Cochrane Risk of Bias 2 tool.
AB - The ARASENS trial recruited 1306 men with metastatic hormone sensitive prostate cancer. It investigated the effect of androgen deprivation therapy (ADT) and systemic therapy docetaxel in combination with a third novel drug – daralutamide, compared with placebo on overall survival. Triple therapy with ADT, docetaxel and darolutamide resulted in improved overall survival rates as compared with ADT, docetaxel and placebo (HR 0.68; 95% CI, 0.57–0.80; p < 0.001). The side effect profile for both treatments was similar. This randomised, double blinded, placebo controlled study, was assessed to have a low risk of bias using the Cochrane Risk of Bias 2 tool.
KW - Daralutamide
KW - Metastatic
KW - Prostate cancer
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=85197308350&partnerID=8YFLogxK
U2 - 10.1186/s12894-024-01507-7
DO - 10.1186/s12894-024-01507-7
M3 - Comment/debate
C2 - 38951868
AN - SCOPUS:85197308350
SN - 1471-2490
VL - 24
JO - BMC Urology
JF - BMC Urology
IS - 1
M1 - 135
ER -
